KR101301777B1 - Ｃｈｋ1을 억제시키는데 유용한 화합물 - Google Patents

Ｃｈｋ1을 억제시키는데 유용한 화합물 Download PDF

Info

Publication number
KR101301777B1
KR101301777B1 KR1020117013801A KR20117013801A KR101301777B1 KR 101301777 B1 KR101301777 B1 KR 101301777B1 KR 1020117013801 A KR1020117013801 A KR 1020117013801A KR 20117013801 A KR20117013801 A KR 20117013801A KR 101301777 B1 KR101301777 B1 KR 101301777B1
Authority
KR
South Korea
Prior art keywords
cancer
pyrazol
ylamino
methoxyphenyl
carbonitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020117013801A
Other languages
English (en)
Korean (ko)
Other versions
KR20110084539A (ko
Inventor
프랑신 에스. 파로우즈
리안 코트스워드 홀콤브
라메쉬 카사
스티븐 스콧 마이어스
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20110084539A publication Critical patent/KR20110084539A/ko
Application granted granted Critical
Publication of KR101301777B1 publication Critical patent/KR101301777B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020117013801A 2008-12-17 2009-12-10 Ｃｈｋ1을 억제시키는데 유용한 화합물 Expired - Fee Related KR101301777B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13817608P 2008-12-17 2008-12-17
US61/138,176 2008-12-17
PCT/US2009/067437 WO2010077758A1 (en) 2008-12-17 2009-12-10 Compounds useful for inhibiting chk1

Publications (2)

Publication Number Publication Date
KR20110084539A KR20110084539A (ko) 2011-07-25
KR101301777B1 true KR101301777B1 (ko) 2013-08-30

Family

ID=42079067

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117013801A Expired - Fee Related KR101301777B1 (ko) 2008-12-17 2009-12-10 Ｃｈｋ1을 억제시키는데 유용한 화합물

Country Status (37)

Country Link
EP (1) EP2379532B1 (enExample)
JP (1) JP5705743B2 (enExample)
KR (1) KR101301777B1 (enExample)
CN (1) CN102245597B (enExample)
AR (1) AR074471A1 (enExample)
AU (1) AU2009333433B2 (enExample)
BR (1) BRPI0922468A2 (enExample)
CA (1) CA2746423C (enExample)
CL (1) CL2011001463A1 (enExample)
CO (1) CO6382122A2 (enExample)
CR (1) CR20110339A (enExample)
CY (1) CY1113930T1 (enExample)
DK (1) DK2379532T3 (enExample)
DO (1) DOP2011000185A (enExample)
EA (1) EA018118B1 (enExample)
EC (1) ECSP11011136A (enExample)
ES (1) ES2401558T3 (enExample)
HN (1) HN2011001446A (enExample)
HR (1) HRP20130167T1 (enExample)
IL (1) IL213160A (enExample)
JO (1) JO2886B1 (enExample)
MA (1) MA32901B1 (enExample)
MX (1) MX2011006603A (enExample)
MY (1) MY156998A (enExample)
NZ (1) NZ593440A (enExample)
PA (1) PA8850801A1 (enExample)
PE (1) PE20120077A1 (enExample)
PL (1) PL2379532T3 (enExample)
PT (1) PT2379532E (enExample)
RS (1) RS52739B (enExample)
SG (1) SG172222A1 (enExample)
SI (1) SI2379532T1 (enExample)
TN (1) TN2011000298A1 (enExample)
TW (1) TWI436996B (enExample)
UA (1) UA101998C2 (enExample)
WO (1) WO2010077758A1 (enExample)
ZA (1) ZA201103946B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314108B2 (en) * 2008-12-17 2012-11-20 Eli Lilly And Company 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts
JO3145B1 (ar) * 2010-11-08 2017-09-20 Lilly Co Eli مركبات مفيدة لتثبيط chk1
GB201402277D0 (en) * 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
TWI725041B (zh) * 2015-07-23 2021-04-21 美商美國禮來大藥廠 用於治療神經母細胞瘤及/或軟組織肉瘤之chk1/2抑制劑
TWI627168B (zh) * 2015-12-07 2018-06-21 美國禮來大藥廠 (s)-乳酸鹽
SG11201803903YA (en) * 2015-12-15 2018-06-28 Lilly Co Eli Combination therapy for cancer
WO2017132928A1 (en) * 2016-02-04 2017-08-10 Pharmaengine, Inc. 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications
AU2018243667A1 (en) 2017-03-31 2019-10-17 Seagen Inc. Combinations of Chk1- and Wee1 - inhibitors
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
CN112457306A (zh) 2019-09-06 2021-03-09 上海瑛派药业有限公司 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
US11634424B2 (en) 2019-11-29 2023-04-25 Medshine Discovery Inc. Diazaindole derivative and use thereof as CHK1 inhibitor
WO2021119236A1 (en) 2019-12-10 2021-06-17 Seagen Inc. Preparation of a chk1 inhibitor compound
US11564920B2 (en) 2020-11-30 2023-01-31 Sumitomo Pharma Co., Ltd. 5-heteroaryl-1H-pyrazol-3-amine derivative
AU2021389190A1 (en) 2020-11-30 2023-06-29 Sumitomo Pharma Co., Ltd. 5-heteroaryl-1h-pyrazol-3-amine derivative
KR20240021188A (ko) * 2021-05-27 2024-02-16 바운드리스 바이오, 인크. 체크포인트 키나제 1(chk1) 억제제 및 그의 용도
GB202107932D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd Preparation of a CHK1 Inhibitor Compound
GB202107924D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd A pharmaceutical salt
MX2024007910A (es) 2021-12-24 2024-09-04 Sumitomo Pharma Co Ltd Derivado de 1h-pirazol-3-amina que tiene una estructura principal bicíclica.
EP4534100A1 (en) * 2022-05-27 2025-04-09 Sumitomo Pharma Co., Ltd. Therapeutic for cancer refractory to immune checkpoint inhibitor
JP7546104B2 (ja) * 2022-05-27 2024-09-05 住友ファーマ株式会社 ５－ヘテロアリール－１ｈ－ピラゾール－３－アミン誘導体からなる医薬
GB202213792D0 (en) 2022-09-21 2022-11-02 Benevolentai Bio Ltd New compounds and method
GB202403910D0 (en) 2024-03-19 2024-05-01 Benovental Cambridge Ltd New processes and intermediates for pharmaceutical products

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014876A1 (en) 2002-08-13 2004-02-19 Abbott Laboratories Urea derivatives as kinase inhibitors
WO2005009435A1 (en) 2003-07-25 2005-02-03 Pfizer Inc. Aminopyrazole compounds and use as chk1 inhibitors
WO2008117050A1 (en) 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090270418A1 (en) * 2008-01-09 2009-10-29 Marianne Sloss Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014876A1 (en) 2002-08-13 2004-02-19 Abbott Laboratories Urea derivatives as kinase inhibitors
WO2005009435A1 (en) 2003-07-25 2005-02-03 Pfizer Inc. Aminopyrazole compounds and use as chk1 inhibitors
WO2008117050A1 (en) 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer

Also Published As

Publication number Publication date
PE20120077A1 (es) 2012-02-06
NZ593440A (en) 2013-02-22
TN2011000298A1 (en) 2012-12-17
MY156998A (en) 2016-04-15
HRP20130167T1 (hr) 2013-03-31
ZA201103946B (en) 2012-10-31
CN102245597A (zh) 2011-11-16
CA2746423A1 (en) 2010-07-08
EP2379532B1 (en) 2013-02-20
JP2012512249A (ja) 2012-05-31
PL2379532T3 (pl) 2013-07-31
CR20110339A (es) 2011-09-14
MA32901B1 (fr) 2011-12-01
CY1113930T1 (el) 2016-07-27
ECSP11011136A (es) 2011-07-29
AU2009333433A1 (en) 2011-06-30
EA018118B1 (ru) 2013-05-30
RS52739B (sr) 2013-08-30
SG172222A1 (en) 2011-07-28
PT2379532E (pt) 2013-03-25
CL2011001463A1 (es) 2012-01-20
UA101998C2 (ru) 2013-05-27
IL213160A (en) 2013-12-31
TWI436996B (zh) 2014-05-11
TW201029994A (en) 2010-08-16
BRPI0922468A2 (pt) 2020-08-04
AR074471A1 (es) 2011-01-19
KR20110084539A (ko) 2011-07-25
PA8850801A1 (es) 2010-07-27
IL213160A0 (en) 2011-07-31
EA201170834A1 (ru) 2011-12-30
WO2010077758A1 (en) 2010-07-08
ES2401558T3 (es) 2013-04-22
EP2379532A1 (en) 2011-10-26
CA2746423C (en) 2014-01-14
HN2011001446A (es) 2013-08-05
DK2379532T3 (da) 2013-03-18
SI2379532T1 (sl) 2013-05-31
DOP2011000185A (es) 2017-12-15
AU2009333433B2 (en) 2012-06-14
HK1160110A1 (en) 2012-08-10
CO6382122A2 (es) 2012-02-15
CN102245597B (zh) 2014-04-16
JP5705743B2 (ja) 2015-04-22
MX2011006603A (es) 2011-09-27
JO2886B1 (en) 2015-03-15

Similar Documents

Publication Publication Date Title
KR101301777B1 (ko) Ｃｈｋ1을 억제시키는데 유용한 화합물
JP2013510824A (ja) セリン／トレオニンキナーゼを調節または制御するための化合物、その調製のための方法、医薬組成物、化合物の使用、方法ならびにセリン／トレオニンキナーゼ調節剤
US8314108B2 (en) 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts
CA2506773A1 (en) Heteroaryl-pyramidine derivatives as jak inhibitors
US20080207632A1 (en) Protein kinase inhibitors
KR101533166B1 (ko) Ｃｈｋ１ 억제에 유용한 화합물
JP2009227682A (ja) Ｃｈｋ１阻害に有用なヘテロアリール尿素誘導体
CN119546588A (zh) 吡啶检查点激酶1（chk1）抑制剂及其用途
US20090029982A1 (en) Protein kinase inhibitors
US11123326B2 (en) CHK1/2 inhibitors and irinotecan for use in the treatment of rhabdomyosarcoma
AU2015290176A1 (en) Quinoxaline compounds, method for preparing the same and use thereof
HK1160110B (en) Compounds useful for inhibiting chk1
Asl et al. Synthesis, biological evaluation, and docking analysis of novel benzimidazole–triazole hybrids as potential anticancer agents
Davadra Synthesis and Biological Activity of Organic Compounds
EP2714689A1 (en) Amino-substituted-alkyloxy-benzo[e]pyrido[4,3-b]indole derivatives as new potent kinase inhibitors

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20160629

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20180628

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20190624

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20200824

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20200824